Briefing
HPV16 circulating tumour DNA for prognostic stratification and post-treatment surveillance in HPV-positive oropharyngeal cancer: A multinational study
In a multinational cohort of 173 patients with HPV-positive oropharyngeal cancer, an HPV16 E6 droplet-digital PCR assay had 100% specificity and 73.4% sensitivity at baseline. Higher pretreatment ctDNA levels were independently associated with worse overall survival (HR 1.68). In 72 patients followed after treatment, persistent HPV ctDNA was associated with progression or recurrence 6.3 to 23.0 months after therapy ended.
- Design: Evidence level 2
- Assay: ddPCR
European Journal of CancerPubMed 42933086DOI 10.1016/j.ejca.2026.117768